In Vivo Testing of Nasal Dosage Forms

By Upperton Pharma Solutions

Interest in developing nasal dosage forms has increased significantly in the last two years, driven by a number of recent successful FDA approvals such as BAQSIMI庐 (dry-powder glucagon) NEFFY庐 (liquid epinephrine spray) and NARCAN庐 (liquid naloxone spray).

In all of these cases, drugs that have previously been administered via the subcutaneous route have been re-developed as nasal dosage forms that offer a more patient-friendly and needle-free administration option.

To read more, please download this free white paper.

Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sections

Sections

Sections

Sections

Sections